BARDA RESEARCH

Explore the science of medical countermeasures innovation and ways BARDA scientists improve public health emergency preparedness and response

BARDA Research

BARDA scientists and their industry collaborators improve and develop medical countermeasures by driving innovation beyond traditional boundaries.

The Science Behind Medical Countermeasures: BARDA’s scientists push new ways to approach development of products for public health emergencies. By improving the science of medical countermeasures, BARDA research enhances the nation’s emergency preparedness. Learn more about BARDA’s scientists and their work to advance medical countermeasure development and deployment.
Page 0 of 0
Featured

COVID 

Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
Description

Viral respiratory infections predispose patients to bacterial infections and have been a major contributor to death in previous pandemics. The association of secondary bacterial infections and COVID-19 patient outcomes has not been well studied. Our study collected case data from physicians to better understand bacterial infections in hospitalized COVID-19 patients. We found that unresolved bacterial infections contributed significantly to death, thus warranting additional research to better prepare for future pandemics.

BARDA Authors

Jacobs, Anna C., PhD; Khosrowshawhi, Lynn, MPH; Risi, George, MD; Beekmann, Susan, MPH; Polgreen, Philip M., MD, MPH; Albrecht, Mark, PhD

Keywords
BARDA Research, CBRN, Antibacterials Branch, antimicrobial resistance, secondary infection, co-infection, sepsis, pandemic, COVID-19
Read Full Article or Abstract
Anna C. Jacobs, Lynn Khosrowshahi, George Risi, Susan Beekmann, Philip M. Polgreen, the COVID-19 Study Team, and Mark Albrecht. Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey. COVID 2022, 2(5): 649-659.
Human Vaccines & Immunotherapeutics
Partnering on vaccines to counter multi-drug resistant threats: workshop proceedings, biomedical advanced research and development authority
Partnering on vaccines to counter multi-drug resistant threats: workshop proceedings, biomedical advanced research and development authority
Description

The rate of antimicrobial resistance (AMR) is increasing, particularly in pathogens for which there are few or no alternative therapeutics available. The workshop sought to understand the challenges that product developers encounter when developing vaccines for AMR pathogens. Participants from industry, government, and academia developed recommendations for overcoming these challenges, which included more funding for early- and late-stage development and refinement of target populations and indications.

 

BARDA Authors

Bergmann, Julie N.; Killens-Cade, Rushyannah R.; Parish, Lindsay A.; Albrecht, Mark T.; Wolfe, Daniel N.

Keywords
Workshop, Vaccines, Multi-drug Resistant Threats, BARDA
Read Full Article or Abstract
Julie N. Bergmann, Rushyannah R. Killens-Cade, Lindsay A. Parish, Mark T. Albrecht & Daniel N. Wolfe (2022) Partnering on vaccines to counter multi-drug resistant threats: workshop proceedings, biomedical advanced research and development authority, Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2022.2058840

Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Description

After a mass casualty incident involving a nerve agent, large quantities of atropine may be needed to treat victims. Identifying contingency sources of atropine is critical when fielded atropine autoinjectors and IV doses are insufficient to treat all exposed. In this Phase I Clinical Trial, atropine eyedrops were administered sublingually and their bioavailability was compared to IV administration of atropine to evaluate the sublingual route as a viable alternative treatment route in a mass casualty incident.

BARDA Authors

Schwartz, Michael D, MD; Raulli, Robert, PhD; Laney, Judith, PhD; Coley, William, PhD; Walker, Robert, MD*; O'Rourke, Anna W, MS; Raine, Kathryn; Horwith, Gary, MD; Gao, Yonghong, PhD*; Eisnor, Derek L, MD; Lu, Di, PhD; Wolling, Brenda*; David, Gloria, PhD; Johnson, Keli; Barry, William T, PhD; Chang, Jamie, MD; Jepson, Brett MS; Fein, Melanie MD
*not current BARDA staff but was employed by BARDA at time of authorship 

Keywords
CBRN, Chemical Medical Countermeasures, Nerve Agent, Atropine, Sublingual, Bioavailability, Phase I Clinical Trial, Pharmacokinetics
Read Full Article or Abstract
Michael D Schwartz, Robert Raulli, Judith W Laney, et al. Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure. Journal of Medical Toxicology. 2022 Mar 21. doi: 10.1007/s1

Addition of ketamine to standard-of-care countermeasures for acute organophosphate poisoning improves neurobiological outcomes
Addition of ketamine to standard-of-care countermeasures for acute organophosphate poisoning improves neurobiological outcomes
Description

In an emergency involving nerve agent exposure, immediate administration of treatment is critical to saving lives, but protecting against long-term medical sequelae can be difficult– especially if initial treatment is delayed. This study explored the therapeutic potential of adding ketamine to the current standard of care, including midazolam when treatment is delayed. Results showed that adding ketamine to the standard treatment regimen may provide protection against the long-term neurologic effects of sarin.

BARDA Authors

Lewine, Jeffery David; Weber, Waylon; Gigliotti, Andrew; McDonald, Jacob D.; Doyle-Eisele, Melanie; Bangera, Nitin; Paulson, Kim; Magcalas, Christy; Hamilton, Derek A.; Garcia, Efrain E.; Raulli, Robert E.; Laney, Judith

Keywords
BARDA Research, chemical division, ketamine, nerve agents, behavior, medical countermeasures, seizures, standard of care, OP pesticides
Read Full Article or Abstract
Lewine JD, Weber W, Gigliotti A, McDonald JD, Doyle-Eisele M, Bangera N, Paulson K, Magcalas C, Hamilton DA, Garcia E, Raulli R, Laney J. Addition of ketamine to standard-of-care countermeasures for acute organophosphate poisoning improves neurobiological outcomes. Neurotoxicology. 2018 Dec;69:37-46. doi: 10.1016/j.neuro.2018.08.011. Epub 2018 Aug 30. PMID: 30172622.

The pharmacokinetics of ketamine following intramuscular injection to F344 rats
The pharmacokinetics of ketamine following intramuscular injection to F344 rats
Description

Ketamine is a medication that is readily available to most clinicians in emergency departments, with well-understood effects in humans. The goal of this study was to determine the pharmacokinetic (PK) profile of ketamine following single or repeated intramuscular administrations of subanesthetic levels of ketamine, with or without the nerve agent standard of care treatment. The results of this PK profile support further investigation of the efficacy of ketamine following nerve agent exposure.

BARDA Authors

Moeller, Benjamin; Espelien, Brenna; Weber, Waylon; Doyle-Eisele, Melanie; Garner, Edwin C.; McDonald, Jacob; Garcia, Efrain E.; Raulli, Robert E.; Laney, Judith

Keywords
BARDA Research, CBRN division, ketamine, nerve agents, Pharmacokinetics, pharmacodynamics, behavior, medical countermeasures, seizures
Read Full Article or Abstract
Moeller B, Espelien B, Weber W, Kuehl P, Doyle-Eisele M, Garner CE, McDonald JD, Garcia E, Raulli R, Laney J. The pharmacokinetics of ketamine following intramuscular injection to F344 rats. Drug Test Anal. 2019 Jan;11(1):68-76. doi: 10.1002/dta.2468. Epub 2018 Aug 14. PMID: 30027605; PMCID: PMC6538562.

A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication
A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication
Description

Most research for medical countermeasures against nerve agent exposure assumes a military scenario, in which autoinjector-based treatment is expected to be available immediately. In a civilian setting however, treatment is delayed until the arrival of first responders, which may significantly affect treatment efficacy. The study provides a framework for evaluating the efficacy of treatment administered at a specific stage of the toxidrome (a group of injuries caused by a toxin), when immediate treatment is absent.

BARDA Authors

Cornelissen, Alex S.; Garcia, Efrain E.; Raulli, Robert E.; Laney, Judith; Joosen, Marloes J.A.

Keywords
Scopolamine, nerve agents, Standard of care, SOC, survival, seizure, delayed treatment, histopathology, VX intoxication, nerve agent, SOC, animal model, chem MCM model, Benzodiazepine
Read Full Article or Abstract
Cornelissen AS, Garcia EE, Raulli RE, Laney J, Joosen MJA. A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication. Toxicol Appl Pharmacol. 2021 Sep 15;427:115650. doi: 10.1016/j.taap.2021.115650. Epub 2021 Jul 15. PMID: 34273408.

Nature

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Description

Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with determining vaccine efficacy. However, SARS-CoV-2 nAb data is collected across multiple laboratories and assay types, making it difficult to cross-validate readouts which may impede regulatory decisions on these COVID-19 vaccine candidates. This study evaluates three calibration approaches to achieve a common scale to aid data-driven decision-making on the evaluation of COVID-19 vaccines.

BARDA Authors

Huang, Yunda; Borisov, Oleg V.; Kee, Jia Jin; Carpp, Lindsay N; Wrin, Terri; Cai, Suqin; Sarzotti-Kelsoe, Marcella; McDanal, Charlene; Eaton, Amanda; Pajon, Rolando; Hural, John; Posavad, Christine M.; Gill, Katherine; Karuna, Shelly; Corey, Lawrence; McElrath, M Juliana; Gilbert, Peter B.; Petropoulos, Christos J.; Montefiori, David C.;

Keywords
IEIDD, Vaccine, SARS-CoV-2, Immuno assay, Pseudovirion neutralization assay, antibodies
Read Full Article or Abstract
Yunda Huang, Oleg Borisov, Jia Jin Kee, Lindsay N Carpp, Terri Wrin, Suqin Cai, Marcella Sarzotti-Kelsoe, Charlene McDanal, Amanda Eaton, Rolando Pajon, John Hural, Christine M Posavad, Katherine Gill, Shelly Karuna, Lawrence Corey, M Juliana McElrath, Peter B Gilbert, Christos J Petropoulos, David C Montefiori. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci Rep. 2021 Dec 14;11(1):23921. doi: 10.1038/s41598-021-03154-6.

ScienceDirect

Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries
Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries
Description

Does seasonal influenza vaccination save lives? Who benefits most? Among 26 million beneficiaries participating in traditional (Fee for Service) Medicare during the winter of 2017-2018, about half had accepted influenza vaccination. The greatest benefit accrued to ambulatory beneficiaries, with those accepting vaccination having a relative risk of death (all other things being equal) of 0.87, meaning a 13% reduction. A vaccination benefit extended even to aged (85+) who would have sepsis.

BARDA Authors

All Authors: Buchman, Timothy G. PhD, MD; Simpson, Steven Q. MD; Sciarretta, Kimberly L. PhD; Finne, Kristen P.; Sowers, Nicole; Collier, Michael; Chavan, Saurabh; Do, Rose; Lin, Cheng; Oke, Ibijoke; Rhodes, Kiersten E.; Santhosh, Aathira; Sandhu, Alexander T.; Chu, Steve; Patel, Sandeep A., PhD; Disbrow, Gary L. PhD; Bright, Rick A. PhD; MaCurdy, Thomas E.; Kelman, Jeffrey A.

Keywords
DRIVe; Solving Sepsis; Influenza; Vaccine/Vaccination; BARDA Research
Read Full Article or Abstract
Buchman, TG et al. Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries Vaccine, 2021, (in press, published ahead of print) ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2021.11.016. (https://www.sciencedirect.com/science/article/pii/S0264410X21014614)

Vaccines

Selection of Filovirus Isolates for Vaccine Development Programs
Selection of Filovirus Isolates for Vaccine Development Programs
Description

Now that licensed vaccines are available for disease caused by Ebola virus (Zaire species), the US Government is pivoting to vaccine programs to target Sudan ebolavirus and Marburg virus. Absent a large outbreak, licensure of such vaccines may occur via the FDA Animal Rule. Nonclinical development will be critical to the overall success of the programs, including the selection of viral isolates to be used in testing vaccines. This manuscript provides suggested isolates for use in vaccine development.

BARDA Authors

All Authors: Wolfe, Daniel ; Sabourin, Carol; Merchlinsky, Michael; Florence, William; Wolfraim, LarryTaylor, Kimberly; Ward, Lucy

Keywords
ebola; Sudan; Marburg; filovirus; animal rule; viral isolate; challenge strain; CBRN Countermeasures; Vaccine Branch; Ebola; Sudan; Marburg; vaccine
Read Full Article or Abstract
Vaccines 2021, 9(9), 1045; https://doi.org/10.3390/vaccines9091045 (registering DOI)

npj Vaccines

Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults.
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults.
Description

Avian flu A(H7N9) virus has been known to cause severe, often fatal, lower respiratory disease in humans. We report the findings of a clinical study evaluating the safety and immunogenicity of a new recombinant hemagglutinin H7 subtype influenza vaccine in healthy adults. The recombinant H7 vaccine was safe and well-tolerated, with a safety and immunogenicity profile comparable to that of the egg-/cell-based vaccines produced in response to the A(H7N9) viruses from the 2013 epidemic wave. The results from this study provide critical information to develop a pandemic response strategy and support regulatory requirements for vaccination under Emergency Use Authorization.

BARDA Authors

Christine M. Oshansky, James King, Di Lu, James Zhou, Corrina Pavetto, Gary Horwith, Karen Biscardi, Bai Nguyen, John J. Treanor, Li-Mei Chen, Brett Jepson, Chad Colfer, Pennie Hylton, James Little, Michael O’Hara, Silvija Tresnjak-Smith, Robert Walker, Bai Yeh, Rick A. Bright, Robert A. Johnson, Vittoria Cioce, Ruben O. Donis

Keywords
influenza, pandemic, NPIVS, adjuvant, H7N9, highly pathogenic avian influenza, vaccine
Read Full Article or Abstract
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults. npj Vaccines 6, 41 (2021). https://doi.org/10.1038/s41541-021-00287-7

Analytical and Bioanalytical Chemistry

Development of a clinical assay to measure chlorinated tyrosine in hair and tissue samples using a mouse chlorine inhalation exposure model
Development of a clinical assay to measure chlorinated tyrosine in hair and tissue samples using a mouse chlorine inhalation exposure model
Description

Chlorine is a toxic industrial chemical with a history of use as a chemical weapon.  Evaluation of acute chlorine exposure is complicated by the virtual lack of reliable biomarkers. Using our new chlorine exposure assay for hair and lung tissue samples and our improved chlorinated tyrosine quantitative assay, we report that chlorine exposure biomarker levels are more abundant and detectable for a greater duration in hair than in lung and blood.  

BARDA Authors

Brooke G. Pantazides, Brian S. Crow, Jennifer Quiñones-González, Jonas W. Perez, Jill A. Harvilchuck, Jeffrey J. Wallery, Tom C. Hu, Jerry D. Thomas, Rudolph C. Johnson, and Thomas A. Blake

Keywords
Chlorine gas; 3-chlorotyrosine; 3,5-dichlorotyrosine; in vivo mouse study; LC-MS/MS; hair and lung tissue, CBRN, Chemical Medical Countermeasures
Read Full Article or Abstract
Analytical and Bioanalytical Chemistry (2021) 413:1765–177: Development of a clinical assay to measure chlorinated tyrosine in hair and tissue samples using a mouse chlorine inhalation exposure model. Analytical and Bioanalytical Chemistry. 

Critical Care Medicine

Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018
Description

BARDA partnered with CMS to study and report on sepsis among Medicare beneficiaries. In the first of a 3-paper series, we identified more than 9.5M sepsis inpatient hospital admissions during 2012–2018. Over this interval, annual admission counts increased more than 65% to nearly 1.7M in 2018; the total 2018 cost of sepsis hospitalizations and skilled nursing facility care for beneficiaries exceeded $41.5B, excluding pre/post-stay care or any professional fees. While sepsis mortality continues to decline, it remains quite high (Fig. 3).

BARDA Authors

All Authors: Buchman, Timothy G. PhD, MD; Simpson, Steven Q. MD; Sciarretta, Kimberly L. PhD; Finne, Kristen P. BA; Sowers, Nicole MPP; Collier, Michael BA; Chavan, Saurabh MBBS, MPH; Oke, Ibijoke MPA; Pennini, Meghan E. PhD; Santhosh, Aathira MA; Wax, Marie MBA; Woodbury, Robyn PhD; Chu, Steve JD; Merkeley, Tyler G. MS, MBA; Disbrow, Gary L. PhD; Bright, Rick A. PhD; MaCurdy, Thomas E. PhD; Kelman, Jeffrey A. MD, MMSc

Keywords
cost; Medicare; mortality; sepsis; DRIVe; BARDA Research
Read Full Article or Abstract
Critical Care Medicine: March 2020 - Volume 48 - Issue 3 - p 276-288

Critical Care Medicine

Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018
Description

In paper 2 of 3, we analyzed the trajectories of individual Medicare patients during and after inpatient hospital admissions. While inpatient admission from a nursing facility (vs. from home) was more likely to be due to sepsis, patient characteristics did not otherwise predict whether admission would be due to sepsis or another reason. Sepsis patients consume an increasing fraction of inpatient days and hospital beds. Unfortunately, sepsis has significant adverse effects 6 months after inpatient admission (Fig. 6).

BARDA Authors

All Authors: Buchman, Timothy G. PhD, MD; Simpson, Steven Q. MD; Sciarretta, Kimberly L. PhD; Finne, Kristen P. BA; Sowers, Nicole MPP; Collier, Michael BA; Chavan, Saurabh MBBS, MPH; Oke, Ibijoke MPA; Pennini, Meghan E. PhD; Santhosh, Aathira MA; Wax, Marie MBA; Woodbury, Robyn PhD; Chu, Steve JD; Merkeley, Tyler G. MS, MBA; Disbrow, Gary L. PhD; Bright, Rick A. PhD; MaCurdy, Thomas E. PhD; Kelman, Jeffrey A. MD, MMSc

Keywords
Medicare; mortality; sepsis; trajectory; hospitalization; admission; inpatient
Read Full Article or Abstract
Critical Care Medicine: March 2020 - Volume 48 - Issue 3 - p 289-301

Critical Care Medicine

Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012–2018
Description

Paper 3 in our 3-paper series forecasted long-term costs for Medicare beneficiaries. These informed a lower-bound, rough-order-of-magnitude national cost of $62B/+ for 2019; this estimate included all Americans but excluded pre/post hospital care, professional fees, and costs of care for veterans or active duty military. We forecasted $100B/+ before 2025, noting: “ …financial forecasts are influenced strongly by catastrophic events; appearance of a global pandemic such as the 1918 “Spanish Flu” would incur costs far in excess of financial forecasts generated by the models discussed.” COVID did not yet exist.

BARDA Authors

All Authors: Buchman, Timothy G. PhD, MD; Simpson, Steven Q. MD; Sciarretta, Kimberly L. PhD; Finne, Kristen P. BA; Sowers, Nicole MPP; Collier, Michael BA; Chavan, Saurabh MBBS, MPH; Oke, Ibijoke MPA; Pennini, Meghan E. PhD; Santhosh, Aathira MA; Wax, Marie MBA; Woodbury, Robyn PhD; Chu, Steve JD; Merkeley, Tyler G. MS, MBA; Disbrow, Gary L. PhD; Bright, Rick A. PhD; MaCurdy, Thomas E. PhD; Kelman, Jeffrey A. MD, MMSc

Keywords
forecast; methods; models; sepsis
Read Full Article or Abstract
Critical Care Medicine: March 2020 - Volume 48 - Issue 3 - p 302-318

Vaccine

Evaluation of BioThrax® and AV7909 Anthrax Vaccines in Adults 66 Years of Age or Older
Evaluation of BioThrax® and AV7909 Anthrax Vaccines in Adults 66 Years of Age or Older
Description

We assessed the safety and immunogenicity of Anthrax vaccines in older adults. The results suggest that a CpG adjuvant may help to elicit a protective immune response to anthrax vaccines in those over the age of 65.

BARDA Authors

All Authors: Daniel Wolfe, Eric Espeland, Yonghong Gao, Di Lu, Gretta Blatner, Kathryn Amass (Raine), Gary Horwith, Xiaomi Tong, Robert Hopkins, Gloria David, Brett Jepsen, James King

Keywords
anthrax; vaccine; elderly; clinical trial
Read Full Article or Abstract
Vaccine Volume 38, Issue 50, 25 November 2020, Pages 7970-7976

Human Vaccines and Immunotherapeutics

Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
Description

We detailed some of the lessons learned from the vaccine development perspective, from the response to Ebola (Zaire). In this manuscript, we emphasized the key gaps in product development at the outset of the West Africa epidemic of 2014-2016, and which of those gaps must be imminently filled for vaccines against Ebola (Sudan) and Marburg virus.

BARDA Authors

All Authors: Daniel Wolfe, Marva Taylor, and Amanda Zarrabian

Keywords
Filovirus; Ebola; Sudan ebolavirus; Marburg; vaccine; medical countermeasures
Read Full Article or Abstract
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2020, VOL. 16, NO. 11, 2855-2860

Microorganisms

Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward
Description

We provided a summary of the current status of anthrax vaccines to include those products licensed for use, as well as those currently in clinical development. The manuscript also focuses on some of the near-term research needs.

BARDA Authors

All Authors: Adam Clark and Daniel Wolfe

Keywords
anthrax; Bacillus; anthracis; vaccine
Read Full Article or Abstract
Microorganisms 2020, 8, 651; doi:10.3390/microorganisms8050651
Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
Anna C. Jacobs
Anna C. Jacobs
COVID
May 20, 2022
Partnering on vaccines to counter multi-drug resistant threats: workshop proceedings, biomedical advanced research and development authority
Partnering on vaccines to counter multi-drug resistant threats: workshop proceedings, biomedical advanced research and development authority
Daniel Wolfe
Daniel Wolfe
CBRN
April 3, 2022
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Michael D. Schwartz, MD
Michael D. Schwartz, MD
CBRN
April 19, 2022
Addition of ketamine to standard-of-care countermeasures for acute organophosphate poisoning improves neurobiological outcomes
Addition of ketamine to standard-of-care countermeasures for acute organophosphate poisoning improves neurobiological outcomes
Efrain E. Garcia
Efrain E. Garcia
CBRN
August 30, 2018
The pharmacokinetics of ketamine following intramuscular injection to F344 rats
The pharmacokinetics of ketamine following intramuscular injection to F344 rats
Efrain E. Garcia
Efrain E. Garcia
CBRN
August 14, 2018
A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication
A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication
Efrain E. Garcia
Efrain E. Garcia
CBRN
July 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Oleg V. Borisov
Oleg V. Borisov
IEID
December 14, 2021
Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries
Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries
Timothy Buchman
Timothy Buchman
DRIVe
November 24, 2021
Selection of Filovirus Isolates for Vaccine Development Programs
Selection of Filovirus Isolates for Vaccine Development Programs
Daniel Wolfe
Daniel Wolfe
CBRN
September 19, 2021
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults.
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults.
Christine M. Oshansky
Christine M. Oshansky
IEID
March 9, 2021
Development of a clinical assay to measure chlorinated tyrosine in hair and tissue samples using a mouse chlorine inhalation exposure model
Development of a clinical assay to measure chlorinated tyrosine in hair and tissue samples using a mouse chlorine inhalation exposure model
Tom C. Hu
Tom C. Hu
CBRN
January 28, 2021
Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018
Timothy Buchman
Timothy Buchman
DRIVe
March 2020
Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018
Timothy Buchman
Timothy Buchman
DRIVe
March 2020
Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012–2018
Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012–2018
Timothy Buchman
Timothy Buchman
DRIVe
March 2020
Evaluation of BioThrax® and AV7909 Anthrax Vaccines in Adults 66 Years of Age or Older
Evaluation of BioThrax® and AV7909 Anthrax Vaccines in Adults 66 Years of Age or Older
Daniel Wolfe
Daniel Wolfe
CBRN
November 2020
Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
Daniel Wolfe
Daniel Wolfe
CBRN
March 7, 2020
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward
Daniel Wolfe
Daniel Wolfe
CBRN
April 29, 2020
No results found for that search, please clear your search and try again.